Advertisement

Acute Changes of Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass

  • Yutao Chen
  • Jun LuEmail author
  • Reza Nemati
  • Lindsay D. Plank
  • Rinki MurphyEmail author
Original Contributions
  • 69 Downloads

Abstract

Context

Gastric bypass (GBP) and sleeve gastrectomy (SG) are both effective bariatric treatments that cause sustained weight loss as well as improvement of type 2 diabetes mellitus (T2DM). The underlying mechanisms are under investigation, including the contribution of alterations in bile acids (BAs) in achieving or maintaining the beneficial metabolic effects after bariatric surgery.

Aims

The aim of this study is to investigate the acute and short-term effects of GBP and SG on BA compositions and fibroblast growth factor 19 (FGF19) in obese individuals with T2DM and to evaluate any correlations between changes in these measures with glucose metabolic improvements.

Methods

The levels of both fasting and postprandial plasma BA compositions after oral glucose tolerance test (OGTT), fasting FGF19 and various metabolic indices were measured 1 day before and at 3 days and 3 months after GBP and SG in 19 obese patients (GBP = 8, SG = 11) with T2DM.

Results

Body weight loss was observed after both GBP and SG 3 months post-operatively, with no significant difference between the two intervention groups (15.0 ± 3.1% vs. 13.9 ± 5.2%, P = 0.761).

At 3 days post-operation, FGF19 levels increased significantly in both surgery groups (GBP, 118.3 ± 57.3 vs. 363.6 ± 131.0 pg mL−1, post-operation P = 0.008; SG, 173.2 ± 127.8 vs. 422.0 ± 243.6 pg mL−1, post-operation P = 0.001). Fasting and postprandial increases from pre-operative values in secondary (r = 0.57, P = 0.02; r = 0.58, P = 0.01), conjugated (r = 0.50, P = 0.01; r = 0.48, P = 0.04), glycine-conjugated (r = 0.52, P = 0.05; r = 0.46, P = 0.05) and secondary-conjugated (r = 0.53, P = 0.02; r = 0.60, P = 0.01) BAs correlated with decreases in the postprandial states of glucose (defined by area under the curve (AUC) over 120 min (AUC0-120min)). Increases in postprandial primary-conjugated BAs were found to be associated with decreases in HOMA-IR (r = 0.45, P = 0.05). However, increases in fasting and postprandial taurine-conjugated BA correlated with decreases in both basal insulin secretion rate (r = 0.47, P = 0.04; r = 0.48, P = 0.04) and C-peptide level (r = 0.45, P = 0.05; r = 0.47, P = 0.04).

After 3 months, fasting and postprandial increases in secondary (r = 0.51, P = 0.03; r = 0.48, P = 0.04), secondary-conjugated (r = 0.52, P = 0.02; r = 0.51, P = 0.03) and non-12α-OH (r = 0.51, P = 0.02; r = 0.58, P = 0.01) BAs were found to correlate with increases in Stumvoll Insulin Sensitivity Index. Increases in both fasting and postprandial 12α-OH BAs were correlated with the decreases in glucose AUC (r = 0.46, P = 0.05; r = 0.41, P = 0.04).

Conclusions

Both GBP and SG achieve increases in many BA species as early as 3 days post-operation, which are sustained at 3 months post-operation. Rises in secondary BA and conjugated forms are correlated with early improvements in glucose metabolism at 3 days post-operation. These along with 12α-OH BA correlated with improved glucose metabolism at 3 months post-operation, suggesting they may contribute to the observed T2DM remission after bariatric surgery.

Keywords

Diabetes Sleeve gastrectomy Gastric bypass Bile acids FGF19 

Notes

Acknowledgements

We thank all the participants who took part in this study and the larger clinical research team who made this study possible.

Author Contributions

R.M., J.L. and L.P. conceived the project and designed study. Y.C., R.N. and J.L. performed the sample and/or data collection. Y.C., R.N., J.L., L.P. and R.M. analysed the data. Y.C., R.M., L.P. and J.L. wrote the manuscript. All authors have read and agreed with the final version of this manuscript.

Funding

The main clinical trial was funded by the Waitemata District Health Board. Additional grant for biochemical analyses was obtained from the Faculty of Health and Environmental Sciences, Auckland University of Technology. The funders had no role in the analyses, interpretation of findings, manuscript review or decision to submit the manuscript for publication.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Ethical Statement

All procedures performed consistent with the ethical standards of the New Zealand Health and Disability Ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent Statement

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.CrossRefGoogle Scholar
  2. 2.
    Chang S-H, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA surgery. 2014;149:275–87.CrossRefGoogle Scholar
  3. 3.
    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376:641–51.CrossRefGoogle Scholar
  4. 4.
    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-Centre, randomised controlled trial. Lancet. 2015;386:964–73.CrossRefGoogle Scholar
  5. 5.
    Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2:152–64.CrossRefGoogle Scholar
  6. 6.
    Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859–64.CrossRefGoogle Scholar
  7. 7.
    Penney N, Kinross J, Newton R, et al. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes. 2015;39:1565–74.CrossRefGoogle Scholar
  8. 8.
    Fiorucci S, Mencarelli A, Palladino G, et al. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci. 2009;30:570–80.CrossRefGoogle Scholar
  9. 9.
    Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66:948–83.CrossRefGoogle Scholar
  10. 10.
    Donepudi AC, Boehme S, Li F, et al. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology. 2017;65:813–27.CrossRefGoogle Scholar
  11. 11.
    Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167–77.CrossRefGoogle Scholar
  12. 12.
    Kir S, Kliewer S, Mangelsdorf D. Roles of FGF19 in liver metabolism. In: Cold Spring Harbor symposia on quantitative biology, vol. 2011: Cold Spring Harbor Laboratory Press. p. 139–44.Google Scholar
  13. 13.
    Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high–molecular weight adiponectin levels are increased after bariatric surgery. Metab Clin Exp. 2009;58:1400–7.CrossRefGoogle Scholar
  14. 14.
    Nemati R, Lu J, Dokpuang D, et al. Increased bile acids and FGF19 after sleeve gastrectomy and Roux-en-Y gastric bypass correlate with improvement in type 2 diabetes in a randomized trial. Obes Surg. 2018:1–15.Google Scholar
  15. 15.
    Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity. 2009;17:1671–7.CrossRefGoogle Scholar
  16. 16.
    Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613–9.CrossRefGoogle Scholar
  17. 17.
    Sachdev S, Wang Q, Billington C, et al. FGF 19 and bile acids increase following Roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes. Obes Surg. 2016;26:957–65.CrossRefGoogle Scholar
  18. 18.
    Shimizu H, Hatao F, Imamura K, et al. Early effects of sleeve gastrectomy on obesity-related cytokines and bile acid metabolism in morbidly obese Japanese patients. Obes Surg. 2017;27:3223–9.Google Scholar
  19. 19.
    Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med. 2003;41:1633–41.CrossRefGoogle Scholar
  20. 20.
    Stumvoll M, Van Haeften T, Fritsche A, et al. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001;24:796–7.CrossRefGoogle Scholar
  21. 21.
    Mari A, Schmitz O, Gastaldelli A, et al. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab. 2002;283:E1159–66.CrossRefGoogle Scholar
  22. 22.
    Mari A, Tura A, Gastaldelli A, et al. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002;51:S221–6.CrossRefGoogle Scholar
  23. 23.
    Jahansouz C, Xu H, Hertzel AV, et al. Bile acids increase independently from hypocaloric restriction after bariatric surgery. Ann Surg. 2016;264:1022–8.CrossRefGoogle Scholar
  24. 24.
    Ahmad N, Pfalzer A, Kaplan L. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes. 2013;37:1553–9.CrossRefGoogle Scholar
  25. 25.
    DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387–95.CrossRefGoogle Scholar
  26. 26.
    Abdul-Ghani MA, Matsuda M, Balas B, et al. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30:89–94.CrossRefGoogle Scholar
  27. 27.
    Bose M, Teixeira J, Olivan B, et al. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. J Diabetes. 2010;2:47–55.CrossRefGoogle Scholar
  28. 28.
    Yan H, Tang L, Chen T, et al. Defining and predicting complete remission of type 2 diabetes: a short-term efficacy study of open gastric bypass. Obes Facts. 2013;6:176–84.CrossRefGoogle Scholar
  29. 29.
    Jørgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012;303:E122–31.CrossRefGoogle Scholar
  30. 30.
    Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on β-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes. 2010;34:462–71.CrossRefGoogle Scholar
  31. 31.
    Salinari S, Bertuzzi A, Guidone C, et al. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg. 2013;257:462–8.CrossRefGoogle Scholar
  32. 32.
    Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med. 2015;21:702–14.CrossRefGoogle Scholar
  33. 33.
    Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50:1955–66.CrossRefGoogle Scholar
  34. 34.
    Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with increased plasma levels of 12α−hydroxylated bile acids. Diabetes. 2013:DB_130639.Google Scholar
  35. 35.
    Sweeney TE, Morton JM. The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg. 2013;148:563–9.CrossRefGoogle Scholar
  36. 36.
    Wahlström A, Kovatcheva-Datchary P, Ståhlman M, et al. Crosstalk between bile acids and gut microbiota and its impact on Farnesoid X receptor signalling. Dig Dis. 2017;35:246–50.CrossRefGoogle Scholar
  37. 37.
    Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–59.CrossRefGoogle Scholar
  38. 38.
    Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32:S237–45.CrossRefGoogle Scholar
  39. 39.
    Kübeck R, Bonet-Ripoll C, Hoffmann C, et al. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice. Mol Metab. 2016;5:1162–74.CrossRefGoogle Scholar
  40. 40.
    Dutia R, Embrey M, O'brien S, et al. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes. 2015;39:806–13.CrossRefGoogle Scholar
  41. 41.
    Wahlström A, Sayin SI, Marschall H-U, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41–50.CrossRefGoogle Scholar
  42. 42.
    Risstad H, Kristinsson JA, Fagerland MW, et al. Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial. Surg Obes Relat Dis. 2017;13:1544–53.CrossRefGoogle Scholar
  43. 43.
    Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–31.CrossRefGoogle Scholar
  44. 44.
    Brunetti L, DeSantis EH. Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. Pharm Ther. 2015;40:62.Google Scholar
  45. 45.
    Sandhu S, Moosavi M, Golmohammadi K, et al. Colesevelam as an add-on treatment for control of dyslipidemia and hyperglycemia in type 2 diabetes. Can J Diabetes. 2016;40:112–4.CrossRefGoogle Scholar
  46. 46.
    Coupaye M, Rivière P, Breuil MC, et al. Comparison of nutritional status during the first year after sleeve gastrectomy and Roux-en-Y gastric bypass. Obes Surg. 2014;24:276–83.CrossRefGoogle Scholar
  47. 47.
    Steinert RE, Peterli R, Keller S, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity. 2013;21:E660–8.CrossRefGoogle Scholar
  48. 48.
    Khan FH, Shaw L, Zhang W, et al. Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents. Obesity. 2016;24:2377–83.CrossRefGoogle Scholar
  49. 49.
    Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg. 2012;22:1473–80.CrossRefGoogle Scholar
  50. 50.
    Angelin B, Björkhem I, Einarsson K, et al. Hepatic uptake of bile acids in man: fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest. 1982;70:724–31.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.College of Life and Marine SciencesShenzhen UniversityShenzhenChina
  2. 2.School of Science and School of Interprofessional Health Studies, Faculty of Health and Environmental SciencesAuckland University of TechnologyAucklandNew Zealand
  3. 3.Institute of Biomedical TechnologyAuckland University of TechnologyAucklandNew Zealand
  4. 4.College of Food Engineering and Nutrition SciencesShaanxi Normal UniversityXi’anChina
  5. 5.Department of Surgery, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  6. 6.Auckland Diabetes CentreAuckland District Health BoardAucklandNew Zealand
  7. 7.Whitiora Diabetes DepartmentCounties Manukau District Health BoardAucklandNew Zealand
  8. 8.Department of Medicine, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  9. 9.Maurice Wilkins Centre for BiodiscoveryAucklandNew Zealand

Personalised recommendations